GFM2

Across TCGA pan-cancer cohorts, GFM2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated GFM2 data layer compared with 19 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher GFM2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated GFM2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and GBM show a favorable association.

CCRCC, LUAD, and HNSC are the cancer types where GFM2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	II,III,IV	0.470	0.785	.004	9	view →
LUAD	DFS	Tertile	III,IV	0.478	0.922	.038	6	view →
HNSC	OS	Tertile	III,IV	0.789	0.573	.018	3	view →
GBM	DFS	Median	All	0.796	0.639	.015	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

GFM2–CCRCC (DFS)

Open the CCRCC breakdown →